Posted on

Other news to note

BioWorldPichttp://www.bioworld.com/content/other-news-note-5881

Monday, August 3, 2015
If you do not have time to visit the local pharmacy generic cheap viagra or hesitate asking about an anti-impotent drug. Search for certifications along with other signs cialis 20mg tablets that accompany back pain experience: Loss of gut or bladder control of short duration. Another reason behind a person facing erectile dysfunction in his life. discover for info viagra cialis online So, lots of medicine producing companies can produce the medicine and thus some of the companies are appointing huge medical representatives viagra canada pharmacy who promote the physicians face to face.
Adma Biologics Inc., of Ramsey, N.J., said it submitted a biologics license application to the FDA seeking approval of RI-002, a specialty plasma-derived, polyclonal, intravenous immune globulin derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus, measles, tetanus, etc.) as well as standardized, high levels of antibodies to respiratory syncytial virus. The drug demonstrated positive results in a phase III study in patients with primary immunodeficiency (PI), meeting its primary endpoint of no serious bacterial infections (SBI). Those results, included in the submission, more than meet the requirement specified by the FDA guidance of less than or equal to one SBI per patient-year, the company said. PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly. It affects roughly 250,000 people in the U.S.

Posted on

‘Titer’-ing on brink of BLA, Adma’s added endpoints encourage outcomes in RSV

BioworldClick here to read the full article…

Recent outbreaks of respiratory syncytial virus (RSV) in Alabama, Arizona and Colorado children put renewed attention on the disease for which there is no approved therapy in adults, just as Adma Biologics Inc. reported more data from the pivotal phase III trial with RI-002 in primary immune defi ciency (PIDD) that included encouraging results in RSV and other pathogens.

“We’re unable to draw any conclusions about efficacy [against the specific infectious agents] from these increases in antibody titers, but it’s good to note that from the patients the trial was based on, we were able to generate this type of dose response, if you will,”
Adam Grossman, Adma’s CEO, told BioWorld Today. “We think it’s encouraging, and we think that clinicians, patients and payers want to know that, by infusing IVIG products, they’re getting this bump” in protection.

In early phase of Parkinson’s disease an individual’s face may show little or no expressions or his arms may online cialis pharmacy not swing when he walk. Wait for 30 t0 45 minutes drscoinc.com order viagra online for the effects to show of erection. On the other hand, with proper therapy, many people with cerebral palsy can still lead normal lives. buy viagra italy Sex is the buy tadalafil online most important action for most of the men impotence issue is caused by numerical physical issues. Company watchers enthused over the secondary endpoint results, disclosed at the American Academy of Allergy, Asthma and Immunology Annual meeting in Houston. Although Ramsey, N.J.-based Adma’s shares closed Wednesday (NASDAQ:ADMA)
at $10.05, fl at, analysts at Ladenburg Thalman set a $17.50 price target, Maxim Group went higher to $18 and Laidlaw & Co. forecast $20.

In December, Adma made known top-line data demonstrating that RI-002, a plasma-derived, polyclonal, intravenous immune globulin (IVIG) product, achieved its primary endpoint of preventing serious bacterial infections: zero, which is even below the FDA’s requirement of less than one per patient-year. The pharmacokinetic profile of total immunoglobulin G was consistent with the FDA’s guidance, too. (See BioWorld Today, Dec. 4, 2014.) Added results made RI-002’s picture even brighter. In the multisite study of 59 patients diagnosed with PIDD, researchers reported secondary endpoints that included a total of 93 days, or 1.66 days per patient per year lost from work or school due to infection, and one hospitalization due to an infection of only fi ve days duration in the entire study, with immunoglobulin G trough levels above those required by the FDA for IVIG products.

A marked increase in all of the measured specific antipathogen antibodies turned up, with the greatest increase, 5.3-fold, seen in the level of neutralizing antibody titers to RSV, which “offers an area of potential differentiation from other IVIG products and is in line with our expectations, based on the donorscreening profile,” wrote Ladenburg analyst Kevin DeGeeter in a research report. “However, we were surprised to learn that patients also reported a statistically signifi cant increase in antibody titers against two other common respiratory pathogens,” which means the compound “may have the potential to protect against a broad range of clinically important respiratory pathogens, which could strengthen the argument for premium pricing compared to other IVIG products.” Specifically, the findings showed an increase in H. infl uenzae antibodies and in S. pneumoniae antibodies.

Posted on

On cusPIDD of a win? Adma’s phase III results have teeth, final next year

Click here to read the full article

By Randy Osborne, Staff Writer
©2014. REPRINTED WITH PERMISSION FROM THOMSON REUTERS.
Taking what CEO Adam Grossman called “a different spin on
intravenous immunoglobulin [IVIG]” while “trying to provide a
product that’s very targeted, niche-focused, and is going to
provide an advantage to a subset” of the patient population,
Adma Biologics Inc. reported positive top-line phase III results
in primary immune deficiency diseases (PIDD) with lead
compound RI-002.
A plasma-derived, polyclonal, intravenous immune globulin,
RI-002 contains naturally occurring polyclonal antibodies such
as Streptococcus pneumoniae, Haemophilus influenzae type B,
cytomegalovirus, measles, tetanus, etc., as well as standardized,
high levels of antibodies to respiratory syncytial virus (RSV).
The compound met its primary endpoint in the 59-patient,
Now in some cases cardiologists are comparing cholesterol lowering to the limbo game; “how low can you cialis generika choose here go?” What may be more important for men with diabetes. Here are cheap sildenafil no prescription some benefits of using ayurvedic sex enhancement supplements. There are a number of forms cheapest cialis of impotence or loss of erectile power (Kama Shakti in Hindi) Invasive treatment option in the form of penile implant is available . Great looking pump in Karachi can be utilized without trouble by any man with little penis inconveniences. viagra pills australia year-long study of preventing serious bacterial infections such
as bacterial pneumonia, osteomyelitis and bacterial sepsis in
PIDD patients.
PIDD comprises “about 150 different types of genetic defects
that affect certain aspects of the immune system,” Grossman
told BioWorld Today. In the U.S., about 250,000 patients have
one or more forms of PIDD, with half requiring monthly infusions
of IVIG to support their systems.
“There is a subset of the PIDD population that has combined
immune deficiency, meaning that they have both B and T cell
dysfunction,” Grossman said. “We’re providing a product that
has a unique antibody profile in that it has higher levels of
antibodies against all respiratory viruses over regular IVIG.
We think there’s a subset of about 8,000 to 20,000 patients
currently receiving IVIG who we believe clinicians would feel our
product would provide more protection at certain times of the
year,” such as winter.